Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
In: Journal of Human Hypertension, Jg. 33 (2019-05-01), Heft 7, S. 542-551
Online
unknown
Zugriff:
This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n = 426) received esaxerenone (1.25, 2.5, or 5 mg/day), placebo, or eplerenone (50–100 mg/day) for 12 weeks. The primary efficacy endpoint was the change from baseline in sitting systolic and diastolic blood pressure (BP). Safety endpoints included adverse events and serum K+ elevation. There were significant dose–response reductions in the 2.5 and 5 mg/day esaxerenone groups for sitting BP (both p
Titel: |
Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
|
---|---|
Autor/in / Beteiligte Person: | Okuda, Yasuyuki ; Ito, Sadayoshi ; Rakugi, Hiromi ; Yamakawa, Satoru ; Itoh, Hiroshi |
Link: | |
Zeitschrift: | Journal of Human Hypertension, Jg. 33 (2019-05-01), Heft 7, S. 542-551 |
Veröffentlichung: | Nature Publishing Group UK, 2019 |
Medientyp: | unknown |
ISSN: | 1476-5527 (print) ; 0950-9240 (print) |
Schlagwort: |
|
Sonstiges: |
|